{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06292780\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["linvoseltamab"]],"indication":"relapsed or refractory systemic light chain amyloidosis","name":"LINKER-AL2","nct_id":"NCT06292780","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=linker-al2-nct06292780. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LINKER-AL2","arms":[{"description":"Dose Escalation: Non-Randomized","label":"Phase 1: Cohort 1: Low Dose","type":"EXPERIMENTAL"},{"description":"Dose Escalation: Non-Randomized","label":"Phase 1: Cohort 2: High Dose","type":"EXPERIMENTAL"},{"description":"Dose Expansion: Participants will be randomized in a 1:1 ratio","label":"Phase 2: Low Dose","type":"EXPERIMENTAL"},{"description":"Dose Expansion: Participants will be randomized in a 1:1 ratio","label":"Phase 2: High Dose","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2035-02-20","type":"ESTIMATED"},"conditions":["Relapsed/Refractory Systemic Light Chain Amyloidosis"],"enrollment":{"count":220,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Linvoseltamab","otherNames":["REGN5458","Lynozyfic™"],"type":"DRUG"}],"last_update":"2026-08-18","lead_sponsor":"Regeneron Pharmaceuticals","official_title":"A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-08-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of dose-limiting toxicity (DLTs)","timeFrame":"Up to 28 Days"},{"measure":"Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)","timeFrame":"Up to 3 years"}],"references":[],"start_date":{"date":"2024-08-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)","url":"https://clinicaltrials.gov/study/NCT06292780"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/linker-al2-nct06292780"}